Introduction
Pulmonary artery aneurysms (PAA) are uncommon, with a diverse differential diagnosis. Although most are asymptomatic at diagnosis, fatal aneurysm rupture occurs in one-third and dissection in one-fifth. 1 Hughes-Stovin syndrome (HSS) is a rare condition, characterized by pulmonary/bronchial artery aneurysms and thrombophlebitis, without diagnostic features of Behçet's disease (BD). 2 The diagnostic work-up, role of immunosuppression, anticoagulation and operative indications remain poorly defined.
Case presentation
A 21-year-old male from Missouri, USA was admitted with haemoptysis following 1 month of intermittent fevers, nonproductive cough and weight loss. Past medical history was significant for recurrent oral ulcers. Physical examination found fever, tachycardia and reduced air entry to his right lung base. 
Discussion
Without PAH (mean pulmonary artery pressure 25 mmHg) or features of trauma/iatrogenic injury, congenital abnormalities or connective tissue disorder, the differential diagnosis of PAA is infection vs. vasculitis. Aneurysm-thrombosis complexes, with negative microbiology/mycology testing, suggest HSS or BD-PAI.
Both conditions predominantly affect young males, present with fever and haemoptysis, and involve the right lower lobar artery.
2,3 HLA-B51 is associated with BD and reported in the only case of HSS tested. 2 Due to significant correlation, authors suggest that HSS is a variant form of BD. 2, 3 Recently, the concept of 'vasculo-Behçet's,' with higher frequencies of vascular and cardiac lesions and less ocular, genital or joint involvement has emerged. 4 Operative thresholds for HSS/BD-PAI are controversial and based on case reports. For solitary lesions, we recommend that large (30 mm) or expanding (3 mm in 6 months) aneurysms, PAH and evidence of rupture or dissection should be considered as operative indications based on risk of aneurysm rupture. 1 Multiple, bilateral PAA and small, stable lesions should be treated with immunosuppression. Immunosuppression may stabilize or promote regression of PAA. 2, 5 Transcatheter arterial embolization offers an alternative for inoperable cases. However, long-term outcome data does not exist and the procedures risk aneurysm rupture, distal infarction, and procedural failure, particularly for larger aneurysms. 3 Despite the prothrombotic nature of the condition, anticoagulation carries a high risk of fatal bleeding and has not provided survival benefit in retrospective studies. 3, 6 It should therefore be reserved for cases where the risk of thrombosis clearly outweighs the risk of haemorrhage.
Future research should focus on the immunogenetic relationship between HSS and BD, optimization of immunosuppressive strategies through prospective controlled trials and evaluation of the long-term outcomes of embolization procedures.
